All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld Perspectives » Medical Progress Is Real

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / New Drug application

Medical Progress Is Real

Nov. 6, 2011
By Anette Breindl
No Comments

SAN FRANCISCO ‑ I’m enough of a geek that I actually enjoy the details, devil and all, and so I love covering scientific conferences. At the same time, they can be daunting. So much scientific progress is incremental. A case in point: This year’s conference handbook for the annual meeting of the American Association for the Study of Liver Diseases (AASLD) comes to over 1,500 pages, most of them describing minor advances.

As I sat in a San Francisco café Saturday morning, simultaneously soaking up the atmosphere and sifting through some of those abstracts in preparation for the weekend, though, the title of one such presentation popped out at me.

"Results of Liver Transplantation in a Large Cohort of more than 100 HIV Infected Patients."

When did HIV patients start getting liver transplants? I thought, and then I had something of a flashback (no, not that kind of flashback) to living in the San Francisco Bay Area as a college student in the early 1990s.

I was doing research for my senior thesis. My graduate student mentor was infected with HIV, and one day, he was hospitalized with an infection that went out of control. Absurdly, it had started out pretty much as a pimple.

I remember going to visit him with our lab technician, sitting there in the hospital room, my mentor hooked up to an IV. I don’t remember most of what we talked about, except for this one thing: his saying gloomily, at one point, “I can’t believe I nearly died of a zit.”

I can’t remember what I answered, if anything. Really, there was nothing to say.

Or do.

We could visit him in the hospital. AZT was in clinical trials and one friend, whose lover was HIV-positive, participated in a trial as a healthy control, until he got too sick from the drug and had to drop out. Then his lover died. There was nothing to do, nothing.

My mentor’s story had a happier ending. It turns out, though we did not know it then, that he is an elite controller. He was able to hang on long enough to see the profound medical advances that have turned HIV into a chronic illness.

Today he is a professor, happily immersed in the minutiae of his research. I see him every few years at Neuroscience, where he usually makes a joke about stress being good for his immune system. To the best of my knowledge his liver is not one of his problems, but if it turns into one, maybe he will get a transplant.

I do not mean to make this sound trivial. The study that is being presented at AASLD this year showed a five-year survival rate of slightly more than 50 percent for HIV-infected liver transplant recipients. Those are not great odds.

But back then, he could not have gotten such a transplant at all.

Sometimes, in the day-to-day work of the search for better cures, it feels like the progress is hard to see. But sometimes, even in the little things – especially in the little things, as little as a conference abstract title ‑ it is right there, staring us in the face.

 

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing